Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the…
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
Sen-Jam Pharmaceutical this week announced it is partnering with specialty pharmaceutical manufacturer KVK-Tech for formulation and chemistry, manufacturing and controls for anti-inflammatory injectables. The partnership is the third development, manufacturing, distribution and license agreement the pair have signed. The new partnership will further advance Sen-Jam’s first injectable anti-inflammatory therapeutic, SJP-100. Sen-Jam is developing an immunomodulator…
Genentech, Sanofi both plan to lay off hundreds around San Francisco
Genentech and Sanofi both plan to make significant headcount reductions in the San Francisco area, according to notices filed in the state of California. The San Francisco Chronicle first reported the layoffs. The companies both filed WARN notices to notify the state of their intent to reduce their workforces. Genentech, a Roche unit, will permanently…
Novo Nordisk and Ginkgo Bioworks extend manufacturing, R&D partnership
Ginkgo Bioworks today announced it expanded its strategic partnership with Novo Nordisk to manufacture medicines for chronic diseases. Under the framework agreement, the partnership is slated to run over five years. Ginkgo Bioworks develops a platform for cell programming and biosecurity, while Novo Nordisk develops a series of medications for chronic conditions, including its Wegovy…
Pharmaceutical manufacturer Grindeks opens 28 global subsidiaries
Latvian pharmaceutical manufacturing company Grindeks recently announced it opened 28 new subsidiaries in Europe to develop new products. Grindeks provides a full product lifecycle, including research, development, pharmacovigilance, manufacturing, and sales of original products, generic drugs and active pharmaceutical ingredients. It specializes in cardiology, central nervous system, oncology, diabetes and dermatology. With the new expanded…
Merck initiates Phase 3 trial to assess MK-1084 in combination with Keytruda for certain lung cancers
Merck recently announced it initiated a Phase 3 clinical trial evaluating MK-1084 in combination with Keytruda for treating patients with metastatic non-small cell lung cancer (NSCLC). The Rahway, N.J.-based company is evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with Keytruda to treat patients with NSCLC whose tumors have KRAS G12C mutations…
ProMed Pharma acquires SpineThera’s manufacturing facilities, has option to license IP
ProMed Pharma this week announced it acquired SpineThera’s manufacturing capabilities with the option to license intellectual property. Under the terms of the acquisition, ProMed Pharma has the option to license SpineThera’s microsphere intellectual property, which it could sublicense to ProMed Pharma’s customers. The Plymouth, Minnesota-based contract manufacturer will also add biodegradable microparticle development and manufacturing…
Gilead, Xilio sign license agreement for Xilio tumor-activated immuno-oncology therapy
Gilead and Xilio recently announced an exclusive license agreement to develop and commercialize Xilio’s XTX301, a Phase 1 tumor-activated IL-12 program. Waltham, Massachusetts-based Xilio Therapeutics is a clinical-stage biotechnology company that is developing tumor-activated immuno-oncology therapies. It is using a tumor-activated platform to build tumor-activated molecules, including antibodies, cytokines, bispecifics and cell engagers. Each of…
Cardinal Health starts construction on new pharmaceutical distribution center
Cardinal Health (NYSE:CAH) this week announced it began construction on its new pharmaceutical distribution center in Columbus, Ohio. The new 350,000 sq ft. logistics center will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products to support the company’s pharmaceutical business. Dublin, Ohio-based Cardinal Health’s Consumer Health Logistics Center will…
Astellas breaks ground on €330M manufacturing facility in Ireland
Astellas Pharma announced that it broke ground on a construction site for a state-of-the-art production facility in Ireland. The company invested €330 million in the facility situated at Kerry Technology Park in Tralee, Co. Kerry. Astellas designed the facility with sustainability front of mind. It expects the plant to accelerate the expansion of its in-house…